Business Wire

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Jaa

Knopp Biosciences LLC and the American Partnership for Eosinophilic Disorders (APFED) today announced a partnership to advance awareness of hypereosinophilic syndromes (HES) and to investigate the challenges facing people with the disease.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170906005097/en/

The partnership includes a one-day conference for patients with HES, believed to be the first of its kind, to be held March 23, 2018, in the Washington, D.C. area. This event will bring together patients and researchers to discuss the needs and experiences of people with HES, a rare, systemic inflammatory disease caused by increased levels of a type of white blood cell – the eosinophil – implicated in numerous inflammatory diseases. Knopp and APFED will also develop up-to-date educational materials for patients with HES highlighting advances in understanding the causes of and treatments for the disease.

“APFED is excited to work with Knopp to help shed light on the unique needs and challenges of HES patients,” said APFED’s Executive Director, Mary Jo Strobel. “As we work to increase HES education and advance research of this rare subset of eosinophil-associated disease, bridging researchers and patients is critical. Investigators need a clear understanding of the patients’ journey—how they are diagnosed, how the disease impact daily life, what an ideal treatment looks like? And the patients are eager for information about HES: the clues that research unlocked thus far, how we work together to create improved and meaningful therapies. In the research arena, this is an exciting time for patients with rare eosinophil-associated diseases, such as HES. It is our passion and goal to help patients with these diseases, and we must work together to get there.”

“Knopp is very pleased to forge this partnership with the leading organization for people with eosinophilic disorders,” said Michael Bozik, M.D., president and CEO of Knopp. “As a drug development company targeting HES and other eosinophil-associated diseases, we look forward to collaborating with APFED to deepen our understanding of HES patient needs and to share what we learn with the patient and medical communities.”

Knopp Biosciences is advancing dexpramipexole, an oral drug recently shown to lower eosinophils and corticosteroid requirements in patients with HES. Further clinical studies of dexpramipexole in HES are expected to begin in the first half of 2018.

Details about the March 2018 HES patient conference and a link to register for the event will be available in October on the APFED website, apfed.org, and the Knopp Biosciences website, knoppbio.com.

ABOUT THE AMERICAN PARTNERSHIP FOR EOSINOPHILIC DISORDERS (APFED)

The American Partnership for Eosinophilic Disorders (APFED), based in Atlanta, GA, USA, is a 501(c)3 non-profit organization whose mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. To learn more about APFED and eosinophil-associated diseases, visit apfed.org.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. Please visit knoppbio.com.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Mary Jo Strobel
Executive Director, APFED
+1-713-493-7749
mjstrobel@apfed.org
or
Tom Petzinger
EVP, Knopp Biosciences
+1-412-488-1776
tom@knoppbio.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

California Sports Surfaces Announces New Senior Leadership22.9.2017 23:21Tiedote

The California Sports Surfaces (CSS) brand, as part of ICP Construction (ICP), today announces the appointments of Steve Lock as global vice president; John Graham as leader, strategic accounts and global relationships; and Malcolm Parkes as managing director, Australia California Sports Surfaces. CSS is the leading supplier of such prestigious sports surfacing solutions as DecoTurf, Plexicushion Prestige, Rebound Ace, Premier Sports Coatings, Premier Court and Plexitrac. These world-renowned product lines supply the US Open, the Australian Open and other distinguished sporting events. Steve Lock has assumed the role of global vice president, responsible for managing the US and global sales and marketing teams for California Sport Surfaces. He was previously the leader for California Sports Surfaces in Australia and the Asia/Pacific region, and will be relocating to ICP global headquar

CORRECTING and REPLACING Smiths Detection Wins Biggest Ever Single Order for Next-Generation Hold Baggage Scanner for Frankfurt Airport22.9.2017 19:02Tiedote

Please replace the release with the following corrected version due to multiple revisions to the headline, subhead and body of the release. The corrected release reads: SMITHS DETECTION WINS BIGGEST EVER SINGLE ORDER FOR NEXT-GENERATION HOLD BAGGAGE SCANNER FOR FRANKFURT AIRPORT Advanced HI-SCAN 10080 XCT hold baggage scanners offer flexible, sophisticated detection capabilities Smiths Detection has won its largest single order ever for its advanced HI-SCAN 10080 XCT hold baggage scanners, with an associated eight-year service agreement. The contract covers 35 of our HI-SCAN 10080 XCT next-generation scanners to support the upgrade to the ECAC Standard 3 explosives detection systems. The solution will deliver increased security and operational efficiency, and can easily be upgraded to mee

California Sports Surfaces’ Rebound Ace Portable Court to be Used at Inaugural Laver Cup22.9.2017 17:37Tiedote

California Sports Surfaces (CSS), a brand under ICP Construction (ICP), is pleased to announce its innovative Rebound Ace Portable sport surfacing system is being used in the inaugural Laver Cup in Prague, Czech Republic, Sept. 22-24, 2017. CSS’s Rebound Ace system was selected to provide comfort, consistency and playability to the Laver Cup participants, who represent the best tennis players in the world. For this event, organizers worked with California Sports Surfaces to create a stunning black surface that would keep spectators focused on the game play. Rebound Ace Portable is an interlocking, temporary court system that provides premium cushion and comfort to maximize players’ performance. It has been chosen for use for several high-profile events, including the Fed Cup, Davis Cup, and the Singapore-based WTA Finals, for which it was specifically created. Laver Cup is modeled afte

Mobile RPG ‘King’s Raid’ Set to Launch in European Markets22.9.2017 14:00Tiedote

Mobile RPG “King’s Raid” which was launched in February in Korea, North America and SEA, is officially launching in European Markets (Google Play and Apple App Store) this month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170922005006/en/ Mobile RPG King’s Raid is officially launching in European Markets (Google Play and Apple App Store). It is a Character Collection mobile RPG game full of charming characters and high-end graphics. It includes real-time PvP and large scale Raid content. King’s Raid was launched in February in Korea, North America, and SEA. King’s Raid developed by Vespa Interactive went viral and became a hot Mobile RPG even with limited marketing and lack of brand recognition. As it slowly made the charts in Popularity and Grossing Sales in both markets, it succeeded in reaching the Top 5 in both major App markets in Korea within a month

Smiths Detection is Supplying the Latest Technology for ECAC Standard 3 EDS Upgrade at Frankfurt Airport22.9.2017 14:00Tiedote

Smiths Detection is providing the latest hold baggage scanning technology to support the upgrade to ECAC Standard 3 explosives detection systems at Frankfurt Airport. Awarded by the Procurement Office of the Federal Ministry of the Interior in Germany, the contract includes 35 x HI-SCAN 10080 XCT next generation scanners which will not only detect the explosive threats specified by the new standard, but can also easily be upgraded to meet future requirements to identify evolving threats, such as homemade explosives. Frankfurt is Europe’s second largest airport in terms of cargo and fourth in passenger numbers (over 60 million in 2016) and these figures are expected to continue growing. The new technology will deliver the security and operational efficiencies required by such a busy airport both now and into the future. For deployment ahead of the upcoming ECAC deadline of 20

IBC2017 Reports Record Visitor Numbers in Its 50th Year22.9.2017 12:32Tiedote

In its 50th anniversary, IBC2017 has confirmed a year-on-year increase in visitor numbers, marking a record attendance of 57,669 across the six day event. Visitors from across the expanding media ecosystem had the opportunity to learn about the opportunities offered by technologies - including social media TV, OTT, VR, AR, Cloud, IP, Bots and 5G - and to meet the most intelligent robots. Visitors to the 15 exhibition halls witnessed many exciting new launches; Launch Pad grew year-on-year with a record number of exhibitors; the Future Reality Theatre and Content Everywhere Hub free programmes were packed with diverse and new exciting content, embracing the transformation. Conference delegates packed the Forum to hear from leading experts from Facebook, Google, CNN, HTC Viveport, Dolby, C4 and ITV to discuss and debate the hot topics challenging the industry with a focus on m

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme